Clinical data of patients enrolled in this study
| Case no. | Group | Days | Age | Sex | Diagnosis |
|---|---|---|---|---|---|
| 1 | 9 | 58 | M | MDS/AML | |
| 2 | 16–25 | 20 | 40 | M | AML |
| 3 | 22 | 59 | F | MDS/AML | |
| 4 | 23 | 57 | F | AML | |
| 5 | 25 | 34 | F | AML | |
| 23±2* | 48±12† | ||||
| 6 | 26–35 | 28 | 37 | M | AML |
| 7 | 28 | 49 | F | AML | |
| 8 | 29 | 43 | F | AML | |
| 9 | 29 | 54 | M | AML | |
| 10 | 33 | 44 | M | AML | |
| 11 | 34 | 55 | M | MDS/AML | |
| 30±3* | 47±7† | ||||
| 12 | 36–45 | 36 | 27 | F | AML |
| 13 | 36 | 55 | M | AML | |
| 14 | 36 | 59 | M | MDS/AML | |
| 15 | 36 | 60 | F | MDS/AML | |
| 16 | 38 | 57 | F | AML | |
| 17 | 40 | 54 | M | AML | |
| 18 | 41 | 55 | F | AML | |
| 19 | 42 | 30 | M | AML | |
| 38±3* | 50±13† | ||||
| 20 | 46–55 | 50 | 54 | M | AML |
| 21 | 52 | 40 | M | AML | |
| 22 | 55 | 49 | F | AML | |
| 23 | 55 | 58 | F | AML | |
| 53±2* | 50±8† | ||||
| Age-matched poor engraftment group | |||||
| 1 | Poor | 20 | 30 | M | AML |
| 2 | 21 | 31 | F | AML | |
| 3 | 26 | 55 | M | AML | |
| 4 | 34 | 49 | F | AML | |
| 25±6* | 41±13† | ||||
| Age-matched normocellular group | |||||
| 1 | 20 | F | Nephrosis | ||
| 2 | 27 | F | Lymphadenitis | ||
| 3 | 37 | M | Lymphadenitis | ||
| 4 | 52 | M | Hyperthyroidism | ||
| 5 | 68 | M | Amyloidosis | ||
| 6 | 75 | M | COPD | ||
| 7 | 86 | F | Lymphadenitis | ||
| 52±25† | |||||
Patients were grouped based on the day their clots were sampled. The mean age of each group was not significantly different.
*Indicates the average days and SD after CBSCT in each group. Underlines indicate patients whose bone marrow specimens were obtained multiple times.
†Indicates the average age and SD in each group.
AML, acute myelogenous leukaemia; CBSCT, cord blood stem cell transplantation; COPD, chronic obstructive pulmonary disease; days, sampling days; F, female; M, male; MDS/AML, myelodysplastic syndrome overt AML.